Details

<p>Contributors vii</p> <p>Preface xi</p> <p><b>Section I Foundations for Understanding Antiviral Therapies in HCV</b></p> <p>1 HCV Replication 3<br /><i>Michael R. Beard</i></p> <p>2 Hepatitis C Virus Genotypes 12<br /><i>Scott A. Read and Mark W. Douglas</i></p> <p>3 Immune Responses to HCV: Implications for Therapy 17<br /><i>David G. Bowen</i></p> <p>4 Mechanisms of Action of Antiviral Drugs: The Interferons 25<br /><i>Edmund Tse and Michael R. Beard</i></p> <p>5 Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs 36<br /><i>Fred Poordad and Grace M. Chee</i></p> <p>6 Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors 43<br /><i>Lotte Coelmont Leen Delang Mathy Froeyen Piet Herdewijn and Johan Neyts</i></p> <p>7 Pharmacology and Mechanisms of Action of Antiviral Drugs: Protease Inhibitors 53<br /><i>Laurent Chatel-Chaix Martin Baril and Daniel Lamarre</i></p> <p>8 Measuring Antiviral Responses 60<br /><i>Jean-Michel Pawlotsky and Stephane Chevaliez</i></p> <p><b>Section II Efficacy and Clinical Use of Antiviral Therapies</b></p> <p>9 Genotype 1: Standard Treatment 67<br /><i>Rebekah G. Gross and Ira M. Jacobson</i></p> <p>10 Individually Tailored Treatment Strategies in Treatment-na¨ive Chronic Hepatitis C Genotype 1 Patients 74<br /><i>Johannes Wiegand and Thomas Berg</i></p> <p>11 Genotype 1 Relapsers and Non-responders 84<br /><i>Salvatore Petta and Antonio Craxì</i></p> <p>12 Standard Therapy for Genotypes 2/3 90<br /><i>Kenneth Yan and Amany Zekry</i></p> <p>13 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3 97<br /><i>Alessandra Mangia Leonardo Mottola and Angelo Andriulli</i></p> <p>14 Genotypes 2 and 3 Relapse and Non-response 104<br /><i>Stella Martinez Jose Maria Sanchez-Tapias and Xavier Forns</i></p> <p>15 Hepatitis C Genotype 4 Therapy: Progress and Challenges 113<br /><i>Sanaa M. Kamal</i></p> <p>16 Antivirals in Acute Hepatitis C 127<br /><i>Heiner Wedemeyer</i></p> <p>17 Antivirals in Cirrhosis and Portal Hypertension 132<br /><i>Diarmuid S. Manning and Nezam H. Afdhal</i></p> <p>18 Treatment of Recurrent Hepatitis C Following Liver Transplantation 140<br /><i>Ed Gane</i></p> <p>19 Antiviral Treatment in Chronic Hepatitis C Virus Infection with Extrahepatic Manifestations 150<br /><i>Benjamin Terrier and Patrice Cacoub</i></p> <p>20 Cytopenias: How they Limit Therapy and Potential Correction 160<br /><i>Mitchell L. Shiffman</i></p> <p>21 The Problem of Insulin Resistance and its Effect on Therapy 169<br /><i>Venessa Pattullo and Jacob George</i></p> <p>22 HIV and Hepatitis C Co-infection 177<br /><i>Gail V. Matthews and Gregory J. Dore</i></p> <p>23 HCV and Racial Differences 185<br /><i>Andrew J. Muir</i></p> <p>24 HCV and the Pediatric Population 190<br /><i>Kathleen B. Schwarz</i></p> <p>25 New Horizons: IL28 Direct-acting Antiviral Therapy for HCV 196<br /><i>Alexander J. Thompson John G. McHutchison and Geoffrey W. McCaughan</i></p> <p>Index 215</p>

<p>"I think it is an invaluable respository of knowledge for anyone embarking on a career caring for patients with viral hepatitis. This book summarises the hard won clinical knowledge of the past 20 years." (<i>The Irish Medical Journal</i>, 1 January 2013)</p>

<p><b>Professor Geoff McCaughan</b> is Director of the AW Morrow Liver Centre and Physician in Charge at the Australian National Liver Transplant Unit.</p> <p><b>John McHutchison</b> is a professor of medicine at Duke University Medical Center, and since 2002, Director of the DCRI’s Gastroenterology and Hepatology Research division.</p>

<p>According to the WHO, 170 million people, or 3% of the world's population, are infected with Hepatitis C and at risk of developing liver cirrhosis and/or liver cancer.   3-4 million people each year are newly diagnosed carriers of the virus.</p> <p><b>Advanced Therapy for Hepatitis C Infection</b> provides you with expert guidance from the world's leading hepatologists on the very latest treatment options for patients with the HCV virus. Focusing mainly on the efficacy and clinical use of antiviral therapies, key topics include:</p> <ul> <li>Treatment of recurrent hepatitis C following liver transplantation</li> <li>Antivirals in Cirrhosis and Portal Hypertension</li> <li>HIV and Hepatitis C co-infection</li> <li>Cytopenias: how they limit therapy and potential correction</li> <li>The problem of insulin resistance and its effect on therapy</li> <li>Antivirals in Acute Hepatitis C</li> </ul> <p>In addition, it fully covers the foundations for understanding antiviral therapies in HCV, such as the complex pharmacology and mechanisms of antiviral drugs.  Finally, a chapter on <i>New Horizons: Interleukin 28 and direct-acting antiviral therapy for HCV</i>, offers you a glimpse into the future possibilities for HCV therapy.</p> <p>Edited by a team of outstanding international reputation, <b>Advanced Therapy for Hepatitis C Infection</b> is an essential tool for all hepatologists and gastroenterologists involved in the management of patients with Hepatitis C.</p>

GB